Patents by Inventor Brent McKenzie

Brent McKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor XII inhibitors for the treatment of neurological inflammatory disorders
    Patent number: 9957329
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 1, 2018
    Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • Method of treating inflammatory bowel disease
    Patent number: 9211329
    Abstract: A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 15, 2015
    Assignee: CSL LIMITED
    Inventors: Brent McKenzie, Eugene Maraskovsky
  • Factor XII Inhibitors for the Treatment of Neurological Inflammatory Disorders
    Publication number: 20140378653
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Application
    Filed: January 31, 2013
    Publication date: December 25, 2014
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • METHOD OF TREATMENT
    Publication number: 20130302277
    Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 14, 2013
    Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD., CSL LIMITED
    Inventors: Brendan J. JENKINS, Tracy Lynn PUTOCZKI, Matthias ERNST, Andrew JARNICKI, Brent MCKENZIE
  • Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
    Patent number: 8518888
    Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: August 27, 2013
    Assignees: CSL Limited, Ludwig Institute for Cancer Research Ltd.
    Inventors: Brendan J. Jenkins, Tracy Lynn Putoczki, Matthias Ernst, Andrew Jarnicki, Brent McKenzie
  • METHOD OF TREATING INFLAMMATORY BOWEL DISEASE
    Publication number: 20130164291
    Abstract: A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 27, 2013
    Applicant: CSL Limited
    Inventors: Brent MCKENZIE, Eugene MARASKOVSKY
  • Antigen targeting
    Patent number: 8097430
    Abstract: The present invention provides a method of raising an immune response in an animal. The method comprises administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety wherein the targeting moiety binds to at least one receptor present in circulatory vessels in Gut Associated Lymphoid Tissue. It is preferred that the targeting moiety binds to Mucosal Addressin Cellular Adhesion Molecule-1.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 17, 2012
    Assignee: The Council of Queensland Institute of Medical Research
    Inventors: Brent McKenzie, Jefferey Boyle, Andrew Lew
  • METHOD OF TREATMENT
    Publication number: 20100183544
    Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
    Type: Application
    Filed: October 14, 2009
    Publication date: July 22, 2010
    Applicant: CSL LIMITED
    Inventors: Brendan J. JENKINS, Tracy Lynn PUTOCZKI, Matthias ERNST, Andrew JARNICKI, Brent MCKENZIE
  • Relay vaccine
    Publication number: 20060121031
    Abstract: The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM+ mucosal lymphoid tissue.
    Type: Application
    Filed: December 7, 2004
    Publication date: June 8, 2006
    Inventors: Brent McKenzie, Jefferey Boyle, Andrew Lew
  • Antigen targeting
    Publication number: 20040241175
    Abstract: The present invention provides a method of raising an immune response in an animal. The method comprises administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety wherein the targeting moiety binds to at least one receptor present in circulatory vessels in Gut Associated Lymphoid Tissue. It is preferred that the targeting moiety binds to Mucosal Addressin Cellular Adhesion Molecule-1.
    Type: Application
    Filed: June 23, 2004
    Publication date: December 2, 2004
    Inventors: Brent McKenzie, Jefferey Boyle, Andrew Lew